Posts Tagged ‘intercept’

Results of Phase 3 POISE Trial of Ocaliva® (Obeticholic Acid) for the Treatment of PBC

August 17, 2016
intercept

NEW YORK, Aug. 17, 2016 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that the New England Journal of Medicine published the key results of the Phase 3 POISE trial of Ocaliva (obeticholic acid) for the treatment…

Read More

New Liver Drug Big News for Intercept

March 17, 2014
drugs

New Liver Drug Big News for Intercept Intercept Pharmaceuticals, Inc reported big news, that its new liver drug, obeticolic acid (OCA), can effectively treat primary biliary cirrhosis (PBC), an autoimmune disease that damages bile ducts in the liver. The findings bring the company a step closer to filing for market approval. Intercept is unique for…

Read More